Management of anticoagulation in patients with prostate cancer receiving enzalutamide

Joseph J. Shatzel, Molly M. Daughety, Sven R. Olson, Tomasz (Tom) Beer, Thomas Deloughery

    Research output: Contribution to journalReview article

    4 Citations (Scopus)

    Abstract

    Enzalutamide, a novel, oral androgen receptor antagonist used for the treatment of metastatic, castration-resistant prostate cancer, has been shown to improve overall and progression-free survival, prolong time to initiation of chemotherapy, reduce skeletal-related events, and carry a favorable adverse effect profile. Metastatic prostate cancer is a disease of older men, a population with an increased incidence of medical comorbidities warranting anticoagulation. Prostate cancer itself, along with some of its therapies, is also prothrombotic. Enzalutamide interacts with several anticoagulants through various mechanisms, making their concurrent use clinically challenging. As such, complex decisions about anticoagulation in these patients are frequently encountered by treating physicians. In this review, we describe the potential interactions between enzalutamide and various anticoagulants, and suggest management paradigms based on the current body of knowledge for patients with atrial fibrillation, venous thromboembolism, and mechanical heart valves.

    Original languageEnglish (US)
    Pages (from-to)720-727
    Number of pages8
    JournalJournal of Oncology Practice
    Volume13
    Issue number11
    DOIs
    StatePublished - Nov 1 2017

    Fingerprint

    Prostatic Neoplasms
    Anticoagulants
    Androgen Receptor Antagonists
    Castration
    Heart Valves
    Venous Thromboembolism
    Atrial Fibrillation
    Disease-Free Survival
    Comorbidity
    Physicians
    Drug Therapy
    Incidence
    Therapeutics
    Population
    MDV 3100

    ASJC Scopus subject areas

    • Oncology
    • Oncology(nursing)
    • Health Policy

    Cite this

    Management of anticoagulation in patients with prostate cancer receiving enzalutamide. / Shatzel, Joseph J.; Daughety, Molly M.; Olson, Sven R.; Beer, Tomasz (Tom); Deloughery, Thomas.

    In: Journal of Oncology Practice, Vol. 13, No. 11, 01.11.2017, p. 720-727.

    Research output: Contribution to journalReview article

    Shatzel, Joseph J. ; Daughety, Molly M. ; Olson, Sven R. ; Beer, Tomasz (Tom) ; Deloughery, Thomas. / Management of anticoagulation in patients with prostate cancer receiving enzalutamide. In: Journal of Oncology Practice. 2017 ; Vol. 13, No. 11. pp. 720-727.
    @article{edc8df641a2946c8a641e15dffb13879,
    title = "Management of anticoagulation in patients with prostate cancer receiving enzalutamide",
    abstract = "Enzalutamide, a novel, oral androgen receptor antagonist used for the treatment of metastatic, castration-resistant prostate cancer, has been shown to improve overall and progression-free survival, prolong time to initiation of chemotherapy, reduce skeletal-related events, and carry a favorable adverse effect profile. Metastatic prostate cancer is a disease of older men, a population with an increased incidence of medical comorbidities warranting anticoagulation. Prostate cancer itself, along with some of its therapies, is also prothrombotic. Enzalutamide interacts with several anticoagulants through various mechanisms, making their concurrent use clinically challenging. As such, complex decisions about anticoagulation in these patients are frequently encountered by treating physicians. In this review, we describe the potential interactions between enzalutamide and various anticoagulants, and suggest management paradigms based on the current body of knowledge for patients with atrial fibrillation, venous thromboembolism, and mechanical heart valves.",
    author = "Shatzel, {Joseph J.} and Daughety, {Molly M.} and Olson, {Sven R.} and Beer, {Tomasz (Tom)} and Thomas Deloughery",
    year = "2017",
    month = "11",
    day = "1",
    doi = "10.1200/JOP.2017.022004",
    language = "English (US)",
    volume = "13",
    pages = "720--727",
    journal = "Journal of Oncology Practice",
    issn = "1554-7477",
    publisher = "American Society of Clinical Oncology",
    number = "11",

    }

    TY - JOUR

    T1 - Management of anticoagulation in patients with prostate cancer receiving enzalutamide

    AU - Shatzel, Joseph J.

    AU - Daughety, Molly M.

    AU - Olson, Sven R.

    AU - Beer, Tomasz (Tom)

    AU - Deloughery, Thomas

    PY - 2017/11/1

    Y1 - 2017/11/1

    N2 - Enzalutamide, a novel, oral androgen receptor antagonist used for the treatment of metastatic, castration-resistant prostate cancer, has been shown to improve overall and progression-free survival, prolong time to initiation of chemotherapy, reduce skeletal-related events, and carry a favorable adverse effect profile. Metastatic prostate cancer is a disease of older men, a population with an increased incidence of medical comorbidities warranting anticoagulation. Prostate cancer itself, along with some of its therapies, is also prothrombotic. Enzalutamide interacts with several anticoagulants through various mechanisms, making their concurrent use clinically challenging. As such, complex decisions about anticoagulation in these patients are frequently encountered by treating physicians. In this review, we describe the potential interactions between enzalutamide and various anticoagulants, and suggest management paradigms based on the current body of knowledge for patients with atrial fibrillation, venous thromboembolism, and mechanical heart valves.

    AB - Enzalutamide, a novel, oral androgen receptor antagonist used for the treatment of metastatic, castration-resistant prostate cancer, has been shown to improve overall and progression-free survival, prolong time to initiation of chemotherapy, reduce skeletal-related events, and carry a favorable adverse effect profile. Metastatic prostate cancer is a disease of older men, a population with an increased incidence of medical comorbidities warranting anticoagulation. Prostate cancer itself, along with some of its therapies, is also prothrombotic. Enzalutamide interacts with several anticoagulants through various mechanisms, making their concurrent use clinically challenging. As such, complex decisions about anticoagulation in these patients are frequently encountered by treating physicians. In this review, we describe the potential interactions between enzalutamide and various anticoagulants, and suggest management paradigms based on the current body of knowledge for patients with atrial fibrillation, venous thromboembolism, and mechanical heart valves.

    UR - http://www.scopus.com/inward/record.url?scp=85037116294&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85037116294&partnerID=8YFLogxK

    U2 - 10.1200/JOP.2017.022004

    DO - 10.1200/JOP.2017.022004

    M3 - Review article

    C2 - 29125921

    AN - SCOPUS:85037116294

    VL - 13

    SP - 720

    EP - 727

    JO - Journal of Oncology Practice

    JF - Journal of Oncology Practice

    SN - 1554-7477

    IS - 11

    ER -